The U.S. Food and Drug Administration (FDA) is now reviewing an application from Argenx that seeks approval of …
Articles by Marisa Wexler, MS
In a $3.05 billion deal, Horizon Therapeutics will acquire Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune…
After unanimous votes by the boards of directors of both companies, AstraZeneca has announced it will acquire Alexion…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
The first published case of a person developing ocular myasthenia gravis (MG) secondary to COVID-19 was described in…
Treatment with Argenx‘s investigational therapy efgartigimod leads to significant and early reductions in the severity of generalized…
Altered levels of immune proteins associated with the complement system may be implicated in generalized myasthenia gravis (MG), a…
A patient with three different types of myasthenia gravis (MG)-associated antibodies was described in a recent case report.
Treatment with IMVT-1401 significantly eased symptoms and lowered antibody levels in adults with moderate-to-severe generalized myasthenia gravis (MG),…